ARIAD Pharma Aims To Achieve Sustained Profitability In 2018 - Quick Facts

(RTTNews) - ARIAD Pharmaceuticals Inc. (ARIA) announced the company expects to achieve profitability in 2018 through revenue growth and strategic partnerships over the next three years. The company expects to achieve sustained profitability based on more than $400 million in anticipated product revenue in 2018.

ARIAD Pharma also announced its key strategic objectives for 2015. The company said these objectives are focused on expanded commercial, research and development, and new business development initiatives. ARIAD will begin in 2015 three key Iclusig clinical trials including a randomized, Phase 3 trial in patients with chronic-phase CML (CP-CML) who have experienced failure after imatinib therapy. The company expects to secure a broad partnership in 2015 to co-develop and co-commercialize brigatinib.

ARIAD also reported that its estimated and unaudited financial results for full-year 2014 include: net sales of Iclusig of approximately $55 million; and license revenue of approximately $45 million.